IFRX Long Call Strategy

IFRX (InflaRx N.V.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co.

IFRX (InflaRx N.V.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $182.2M, a beta of 2.44 versus the broader market, a 52-week range of 0.711-2.949, average daily share volume of 1.4M, a public-listing history dating back to 2017, approximately 74 full-time employees. These structural characteristics shape how IFRX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 2.44 indicates IFRX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a long call on IFRX?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current IFRX snapshot

As of May 15, 2026, spot at $2.29, ATM IV 206.40%, IV rank 39.45%, expected move 59.17%. The long call on IFRX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on IFRX specifically: IFRX IV at 206.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 59.17% (roughly $1.36 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IFRX expiries trade a higher absolute premium for lower per-day decay. Position sizing on IFRX should anchor to the underlying notional of $2.29 per share and to the trader's directional view on IFRX stock.

IFRX long call setup

The IFRX long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IFRX near $2.29, the first option leg uses a $2.29 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IFRX chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IFRX shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$2.29N/A

IFRX long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

IFRX long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on IFRX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on IFRX

Long calls on IFRX express a bullish thesis with defined risk; traders use them ahead of IFRX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

IFRX thesis for this long call

The market-implied 1-standard-deviation range for IFRX extends from approximately $0.93 on the downside to $3.65 on the upside. A IFRX long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current IFRX IV rank near 39.45% is mid-range against its 1-year distribution, so the IV signal is neutral; the long call thesis on IFRX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, IFRX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IFRX-specific events.

IFRX long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IFRX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IFRX alongside the broader basket even when IFRX-specific fundamentals are unchanged. Long-premium structures like a long call on IFRX are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current IFRX chain quotes before placing a trade.

Frequently asked questions

What is a long call on IFRX?
A long call on IFRX is the long call strategy applied to IFRX (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With IFRX stock trading near $2.29, the strikes shown on this page are snapped to the nearest listed IFRX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are IFRX long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the IFRX long call priced from the end-of-day chain at a 30-day expiry (ATM IV 206.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a IFRX long call?
The breakeven for the IFRX long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current IFRX market-implied 1-standard-deviation expected move is approximately 59.17%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on IFRX?
Long calls on IFRX express a bullish thesis with defined risk; traders use them ahead of IFRX catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current IFRX implied volatility affect this long call?
IFRX ATM IV is at 206.40% with IV rank near 39.45%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.

Related IFRX analysis